bioavail oral antibiot cystic fibrosi present investig wa design assess absorpt disposit cystic fibrosi patient two commonli use antibiot aminopenicillin epicillin cephalexin ospexin pharmacokinet paramet epicillin patient cf normal control differ number aspect differ found maxim plasma concentr could account manifold increas renal clearanc drug data support idea patient cf exhibit unusu larg rapid renal clearanc certain penicillin